SG156681A1 - Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure - Google Patents

Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Info

Publication number
SG156681A1
SG156681A1 SG200907097-0A SG2009070970A SG156681A1 SG 156681 A1 SG156681 A1 SG 156681A1 SG 2009070970 A SG2009070970 A SG 2009070970A SG 156681 A1 SG156681 A1 SG 156681A1
Authority
SG
Singapore
Prior art keywords
remodeling
ranolazine
treatment
heart failure
combination
Prior art date
Application number
SG200907097-0A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of SG156681A1 publication Critical patent/SG156681A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200907097-0A 2004-11-09 2005-11-09 Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure SG156681A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
SG156681A1 true SG156681A1 (en) 2009-11-26

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907097-0A SG156681A1 (en) 2004-11-09 2005-11-09 Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Country Status (15)

Country Link
US (2) US20060111361A1 (es)
EP (1) EP1809289A1 (es)
JP (1) JP2008519770A (es)
KR (1) KR20070084063A (es)
CN (1) CN101072562A (es)
AU (1) AU2005304421A1 (es)
BR (1) BRPI0517650A (es)
CA (1) CA2586840A1 (es)
IL (1) IL183056A0 (es)
MX (1) MX2007005367A (es)
NO (1) NO20072934L (es)
RU (1) RU2007121707A (es)
SG (1) SG156681A1 (es)
WO (1) WO2006053161A1 (es)
ZA (1) ZA200703697B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101030943B1 (ko) * 2002-05-21 2011-04-28 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여
AU2007292926A1 (en) * 2006-09-08 2008-03-13 Symphony Medical, Inc. Intramyocardial patterning for treating localized anomalies of the heart
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
JP2010514696A (ja) * 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
WO2008127607A2 (en) * 2007-04-11 2008-10-23 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142497T1 (de) * 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AU8026200A (en) * 1999-10-19 2001-04-30 Board Of Regents, The University Of Texas System Treatment of heart disease with cox-2 inhibitors
BR0108452A (pt) * 2000-02-18 2003-04-01 Cv Therapeutics Inc Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
ZA200703697B (en) 2008-09-25
RU2007121707A (ru) 2008-12-20
NO20072934L (no) 2007-08-08
BRPI0517650A (pt) 2008-10-14
JP2008519770A (ja) 2008-06-12
EP1809289A1 (en) 2007-07-25
AU2005304421A1 (en) 2006-05-18
WO2006053161A1 (en) 2006-05-18
WO2006053161A8 (en) 2006-09-14
CA2586840A1 (en) 2006-05-18
MX2007005367A (es) 2007-06-18
CN101072562A (zh) 2007-11-14
US20060111361A1 (en) 2006-05-25
US20090176772A1 (en) 2009-07-09
IL183056A0 (en) 2007-10-31
KR20070084063A (ko) 2007-08-24

Similar Documents

Publication Publication Date Title
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
WO2004010937A3 (en) Method of treating cancer
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
GB0018527D0 (en) Composition
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
MX2021003845A (es) Composiciones para reducir el acido urico serico.
BRPI0518700B8 (pt) combinação contendo vegf-trap, 5-fluorouracila e ácido folínico